A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal

Related Experiment Video

Updated: Mar 23, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

626

Yan Song1, Chunxia Du1, Wen Zhang1

  • 1Department of Medical Oncology, Cancer Hospital (Institute), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

Asia-Pacific Journal of Clinical Oncology
|March 22, 2016
PubMed
Abstract

Insights

Hypothyroidism and hyperlipidemia may predict treatment response in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). These findings suggest potential biomarkers for VEGFR-TKI therapy efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) are a cornerstone treatment for metastatic renal cell carcinoma (mRCC).
  • Predictive biomarkers are crucial for optimizing VEGFR-TKI therapy in mRCC patients.

Purpose of the Study:

  • To investigate the association between treatment response to VEGFR-TKIs and the development of hyperlipidemia and hypothyroidism in mRCC patients.
  • To evaluate hypothyroidism and hyperlipidemia as potential predictive factors for VEGFR-TKI efficacy.

Main Methods:

  • Retrospective analysis of clinical data from 155 mRCC patients treated with first-line VEGFR-TKIs.
  • Survival analysis using Kaplan-Meier curves and Cox regression models.
  • Assessment of response rates (RR) and median progression-free survival (mPFS) in relation to endocrine and lipid profiles.

Main Results:

  • Hypothyroidism developed in 36.8% and hyperlipidemia in 54.9% of patients.
  • Patients with hypothyroidism or hyperlipidemia showed significantly higher response rates and longer mPFS compared to those without (P < 0.05).
  • A dose-dependent relationship was observed between the severity of hypothyroidism/hyperlipidemia and treatment outcomes.

Conclusions:

  • Hypothyroidism and hyperlipidemia are associated with improved response to VEGFR-TKIs in mRCC.
  • These conditions may serve as predictive biomarkers for VEGFR-TKI therapy.
  • Further large-scale studies are needed to validate these findings.
Keywords:
hyperlipidemiahypothyroidismrenal cell carcinomatyrosine kinase inhibitor

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
909